In Vitro Diagnostic Market by Product Type (Reagents, Instruments, and Software & Services), Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications), and End-User Industry (Standalone Laboratories, Hospitals, Academics & Medical Schools, Point Of Care Testing, and Others) – Global Opportunity Analysis and Industry Forecast 2023–2030

In Vitro Diagnostics (IVD) Market

Industry:  Life Sciences & Healthcare | Publish Date: Apr 2023 | No of Pages:  377 | No. Tables:  258 | No. Figures:  225

Market Overview:

In Vitro Diagnostic Market was valued at USD 91.25 billion in 2022, and is predicted to reach USD 118.57 billion by 2030, with a CAGR of 3.2% from 2023 to 2030.

In vitro diagnostics (IVD) is the process of performing medical tests on samples such as blood, urine, or tissue outside the body, typically in a laboratory setting. These tests are conducted to diagnose, monitor, or screen various medical conditions or diseases, including infectious diseases, cancer, genetic disorders, and other similar conditions. 
IVD tests use a range of technologies, including immunoassays, molecular diagnostics, clinical chemistry, and microbiology. The results of these tests are used by healthcare professionals to make informed decisions about patient care and treatment. IVD plays an essential role in healthcare, facilitating early detection of diseases, guiding treatment decisions, and improving patient outcomes.

Rise in incidences of chronic and infectious diseases

Increase in prevalence of chronic and infectious diseases propels demand for in vitro diagnostic techniques as these are the easiest techniques for diagnosis of any disease. According to the World Health Organization (WHO), diseases such as diabetes, cardiovascular diseases, cancer, and chronic respiratory diseases kill around 41 million people each year, which is equivalent to 71% of all deaths globally. In addition, the IVD market has witnessed significant growth, owing to the fast spread of COVID-19 virus, which has, in turn, increased demand for rapid diagnosis of individuals across the world. Industry players have responded to this increased demand by launching innovative solutions.

 

Rapid advancements in medical technology and research

In the past 50 years, IVD technologies have been used only in clinical labs. However, these tests are now being done at home or point-of-care (POC). These tests are accurate, less time-consuming, and can be easily performed. For instance, pregnancy test is performed at home by placing urine sample onto the test kit. Similarly, blood glucose level testing can be done using point-of-care testing devices such as Glucometer. HIV test can also be conducted at home using a mouth swab that is inbuilt with a diagnosis device. The swab collects saliva and provides results in 20 to 40 minutes. Previously, these tests were carried out in clinical laboratories where an blood samples were taken. These advancements along with the emergence of digital pathology have brought significant improvements and contributed toward growth of the global IVD market.

High cost of IVD restrains the market growth

High cost is one of the major factors that acts as a restraint for growth of the in vitro diagnostic (IVD) market. High cost of diagnostic tests can be a barrier for some patients, especially those without insurance or with high-deductible plans. This can limit use of diagnostic testing and prevent some individuals from accessing the healthcare they need. In addition, high cost of developing and manufacturing diagnostic tests can also affect the market by limiting number of new products that are introduced to the market. This can make it difficult for smaller companies to enter the market and limit innovation and progress in the field.

 

Evolution in technologies

As personalized medicine approach is gaining popularity, point-of-care technique of diagnostics has witnessed rapid growth. There are various innovations in the IVD instruments market, owing to growth in demand for quicker diagnosis test results. For instance, in January 2021, BGI Genomics Co. Ltd., received Emergency Use Authorization (EUA) from the FDA for its real-time fluorescent RT-PCR kit for qualitative detection or identification of SARS-CoV-2 nucleic acids in throat swabs and bronchoalveolar lavage fluid (BALF) from individuals suspected of COVID-19. Hence, evolution of technologies is expected to fuel growth of the IVD market.

North America is projected to dominate the in vitro diagnostic market

North America is a large and dynamic market, owing to factors such as an aging population, increase in incidences of chronic diseases, and advances in technology. It is characterized by a high degree of innovation, with many companies developing new products and technologies to meet changing needs of the healthcare system. Moreover, increase in demand for early disease detection and personalized medicine is expected to grow in the coming years.

The market is also driven by rise in adoption of advanced technologies such as digital pathology, companion diagnostics, and personalized medicine. Increase in adoption of laboratory automation and use of big data analytics in the diagnostic process is also expected to drive the market growth. In addition, the industry is composed of a mix of large, multinational companies and smaller, specialized firms. Some of the leading companies in the North America IVD market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Beckman Coulter.

These companies have a strong presence in the market and offer a wide range of diagnostic products and services. For instance, in July 2020, Becton, Dickinson and Company obtained Emergency Use Authorization from the U.S. FDA for its fast diagnostic test for SARS-CoV-2, which uses the BD Veritor Plus System and generates results within 15 minutes. Presence of approximately 25,000 BD Veritor Plus Systems in hospitals, pharmacies, clinics, and urgent care centers throughout the U.S. has expanded access to COVID-19 testing in these healthcare facilities.

The IVD industry in North America is highly regulated, with companies subject to strict guidelines and requirements set by regulatory bodies such as the Food and Drug Administration (FDA) and Health Canada. This is to ensure safety, efficacy and quality of the products. The North America IVD industry is also characterized by a high degree of consolidation and mergers and acquisitions activity. This is driven by the need to achieve economies of scale and gain access to new technologies and products.

Asia-Pacific witnessed substantial growth in the in vitro diagnostic industry

The Asia-Pacific in vitro diagnostics (IVD) market is one of the fastest growing regions for IVD. Growth of the market is driven by factors such as increasingly aging population, growth in prevalence of chronic diseases such as diabetes, cancer, and increase in adoption of advanced diagnostic technologies. According to the International Diabetes Federation, an estimated 74 million adults in India were living with diabetes as of 2021. This has been a major driver of the IVD market in the country, as in-vitro diagnostic tests are essential for early detection and management of chronic diseases such as diabetes.

In addition, focus of governments on improving healthcare infrastructure and presence of global market players such as Siemens Healthineers, Abbott, and Roche Diagnostics further boosts growth of the market. For instance, the Healthy China 2020 initiative by the government of China aims to increase investments in the healthcare industry, improve accessibility and quality of healthcare services, and promote development of new medical technologies. This has led to increase in number of hospitals and clinics, boosting demand for IVD products and services in the country.

Global market players have significant resources to invest in research and development, which enables them to bring advanced and innovative diagnostic products to the market. This drives adoption of newer and more efficient diagnostic technologies, which drives the market growth. in June 2022, Siemens Healthineers announced that the company aims to entirely localize its production in China to improve production capabilities for Asia-Pacific.

 

Competitive Landscape

The in vitro diagnostic industry includes various market players such as BioMerieux, Sysmex Corporation, Qiagen N.V., Bio Rad Laboratories Incorporation, Beckton, Dickinson & Company, Roche Holding, Abbott, Danaher Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific Inc. These market players are adopting several strategies such as product launches, acquisitions, and innovation across various regions to maintain their dominance in the in vitro diagnostic market.

In addition, in May 2022, Becton, Dickinson and Company launched BD COR MX instrument, which integrates and automates complete molecular laboratory workflow, from sample processing to diagnostic test results for large, high-throughput labs.

Moreover, in February 2022, BioMerieux introduced MYACUTECASE, a free mobile application that helps in interpreting results of emergency and critical care biomarker tests using VIDAS. This app support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics.

KEY MARKET SEGMENTS

By Component

  • Reagents

  • Instruments

  • Software & Services

By Technique

  • Immunodiagnostics

  • Hematology

  • Molecular Diagnostics

  • Tissue Diagnostics

  • Clinical Chemistry

  • Other IVD Techniques

By Application

  • Infectious Diseases

  • Cancer

  • Cardiac Diseases

  • Immune System Disorders

  • Nephrological Diseases

  • Gastrointestinal Diseases

  • Other Indications

By End User

  • Stand-alone Laboratories

  • Hospitals

  • Academics and Medical Schools

  • Point of Care Testing

  • Others

By Region

  • North America

    • U.S

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • RoW

    • Latin America

    • Middle East

    • Africa

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2021

USD 95.02 Billion

Revenue Forecast in 2030

USD 118.57 Billion

Growth Rate

CAGR of 3.2% from 2023 to 2030

Analysis Period

2022–2030

Base Year Considered

2022

Forecast Period

2023–2030

Market Size Estimation

Billion (USD)

Growth Factors

Rising incidences of chronic and infectious diseases

Rapid advancements in medical technology and research

Countries Covered

18

Companies Profiled

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 analysts working hours) after purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

column chart pie chart

1.    INTRODUCTION

1.1.     REPORT DESCRIPTION

1.2.     WHO SHOULD READ THIS REPORT 

1.3.     KEY MARKET SEGMENTS

1.4.     RESEARCH METHODOLOGY

1.4.1        SECONDARY RESEARCH

1.4.2        DATA ANALYSIS FRAMEWORK

1.4.3        MARKET SIZE ESTIMATION

1.4.4        FORECASTING

1.4.5        PRIMARY RESEARCH AND DATA VALIDATION

2.    IN VITRO DIAGNOSTICS (IVD) MARKET – EXECUTIVE SUMMARY

2.1.     MARKET SNAPSHOT, 2022 - 2030, MILLION USD

3.    MARKET OVERVIEW

3.1.     MARKET DEFINITION AND SCOPE

3.2.     MARKET DYNAMICS

3.2.1        DRIVERS

3.2.1.1.    RISING INCIDENCES OF CHRONIC AND INFECTIOUS DISEASES TO FUEL MARKET GROWTH

3.2.1.2.    RAPID ADVANCEMENTS IN MEDICAL TECHNOLOGY AND RESEARCH STRENGTHENS THE MARKET

3.2.1.3.    AWARENESS OF EARLY DETECTION AND PREVENTION OF DISEASES AMONG INDIVIDUALS

3.2.2        RESTRAINTS

3.2.2.1.    HIGH COST OF IVD RESTRANS INDUSTRY GROWTH

3.2.2.1     STRINGENT REGULATORY POLICIES TO IMPEDE THE GROWTH OF THE MARKET

3.2.3        OPPORTUNITIES

3.2.3.1.    INTRODUCTION OF NEW TECHNOLOGY IN IVD TO INTRODUCE FUTURE OPPORTUNITIES

3.2.3.1     EVOLUTION IN THE TECHNOLOGIES ALLOWS FUTURE MARKET PROSPECTS

4.    GLOBAL IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

4.1.     OVERVIEW

4.2.     REAGENTS

4.2.1        REAGENTS MARKET, BY REGION

4.3.     INSTRUMENTS

4.3.1        INSTRUMENTS MARKET, BY REGION

4.4.     SOFTWARE AND SERVICES

4.4.1        SOFTWARE AND SERVICES MARKET, BY REGION

5.    GLOBAL IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

5.1.     OVERVIEW

5.2.     IMMUNODIAGNOSTICS

5.2.1        GLOBAL IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

5.2.1.1.    ELISA MARKET, BY REGION

5.2.1.2.    RAPID TESTS MARKET, BY REGION

5.2.1.3.    ELISPOT  MARKET, BY REGION

5.2.1.4.    RADIOIMMUNOASSAY (RIA) MARKET, BY REGION

5.2.1.5.    WESTERN BLOT MARKET, BY REGION

5.2.2        IMMUNODIAGNOSTICS  MARKET, BY REGION

5.3.     HEMATOLOGY

5.3.1        HEMATOLOGY MARKET, BY REGION

5.4.     MOLECULAR DIAGNOSTICS

5.4.1        GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

5.4.1.1.    PCR MARKET, BY REGION

5.4.1.2.    INAAT  MARKET, BY REGION

5.4.1.3.    HYBRIDIZATION MARKET, BY REGION

5.4.1.4.    DNA DIAGNOSTICS  MARKET, BY REGION

5.4.1.5.    MICROARRAY  MARKET, BY REGION

5.4.1.6.    OTHERS MARKET, BY REGION

5.4.2        MOLECULAR DIAGNOSTICS MARKET, BY REGION

5.5.     TISSUE DISGNOSTICS

5.5.1        TISSUE DISGNOSTICS  MARKET, BY REGION

5.6.     CLINICAL CHEMISTRY

5.6.1        GLOBAL CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

5.6.1.1.    BASIC METABOLIC PANEL  MARKET, BY REGION

5.6.1.2.    LIVER PANEL MARKET, BY REGION

5.6.1.3.    RENAL PROFILE MARKET, BY REGION

5.6.1.4.    LIPID PROFILE MARKET, BY REGION

5.6.1.5.    THYROID FUNCTION PANEL  MARKET, BY REGION

5.6.1.6.    ELECTROLYTE PANEL  MARKET, BY REGION

5.6.1.7.    SPECIALITY CHEMICALS MARKET, BY REGION

5.6.2        CLINICAL CHEMISTRY  MARKET, BY REGION

5.7.     OTHER IVD TECHNIQUES

5.7.1        OTHER IVD TECHNIQUES MARKET, BY REGION

6.    GLOBAL IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

6.1.     OVERVIEW

6.2.     INFECTIOUS DISEASES

6.2.1        INFECTIOUS DISEASES  MARKET, BY REGION

6.3.     CANCER

6.3.1        CANCER  MARKET, BY REGION

6.4.     CARDIAC DISEASES

6.4.1        CARDIAC DISEASES  MARKET, BY REGION

6.5.     IMMUNE SYSTEM DISORDERS

6.5.1        IMMUNE SYSTEM DISORDERS MARKET, BY REGION

6.6.     NEPHROLOGICAL DISEASES

6.6.1        NEPHROLOGICAL DISEASES MARKET, BY REGION

6.7.     GASTROINTESTINAL DISEASES

6.7.1        GASTROINTESTINAL DISEASES MARKET, BY REGION

6.8.     OTHER INDICATIONS

6.8.1        OTHER INDICATIONS MARKET, BY REGION

7.    GLOBAL IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

7.1.     OVERVIEW

7.2.     STAND ALONE LABORATORY

7.2.1        STAND ALONE LABORATORY MARKET, BY REGION

7.3.     HOSPITALS

7.3.1        HOSPITALS MARKET, BY REGION

7.4.     ACADEMICS AND MEDICAL SCHOOLS

7.4.1        ACADEMICS AND MEDICAL SCHOOLS MARKET, BY REGION

7.5.     POINT OF CARE TESTING

7.5.1        POINT OF CARE TESTING MARKET, BY REGION

7.6.     OTHERS

7.6.1        OTHERS MARKET, BY REGION

8.    GLOBAL IN VITRO DIAGNOSTICS (IVD) MARKET, BY REGION

8.1.     OVERVIEW

8.2.     NORTH AMERICA

8.2.1        NORTH AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.2.2        NORTH AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.2.2.1.    NORTH AMERICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.2.2.2.    NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.2.2.3.    NORTH AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.2.3        NORTH AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.2.4        NORTH AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.2.5        NORTH AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY

8.2.5.1.    U.S.

8.2.5.1.1.    U.S. IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.2.5.1.2.    U.S. IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.2.5.1.2.1.   U.S. IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.2.5.1.2.2.   U.S. MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.2.5.1.2.3.   U.S. CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.2.5.1.3.    U.S. IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.2.5.1.4.    U.S. IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.2.5.2.    CANADA

8.2.5.2.1.    CANADA IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.2.5.2.2.    CANADA IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.2.5.2.2.1.   CANADA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.2.5.2.2.2.   CANADA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.2.5.2.2.3.   CANADA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.2.5.2.3.    CANADA IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.2.5.2.4.    CANADA IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.2.5.3.    MEXICO

8.2.5.3.1.    MEXICO IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.2.5.3.2.    MEXICO IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.2.5.3.2.1.   MEXICO IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.2.5.3.2.2.   MEXICO MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.2.5.3.2.3.   MEXICO CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.2.5.3.3.    MEXICO IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.2.5.3.4.    MEXICO IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.3.     EUROPE

8.3.1        EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.3.2        EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.3.2.1.    EUROPE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.3.2.2.    EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.3.2.3.    EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.3.3        EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.3.4        EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.3.5        EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY

8.3.5.1.    GERMANY

8.3.5.1.1.    GERMANY IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.3.5.1.2.    GERMANY IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.3.5.1.2.1.   GERMANY IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.3.5.1.2.2.   GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.3.5.1.2.3.   GERMANY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.3.5.1.3.    GERMANY IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.3.5.1.4.    GERMANY IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.3.5.2.    FRANCE

8.3.5.2.1.    FRANCE IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.3.5.2.2.    FRANCE IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.3.5.2.2.1.   FRANCE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.3.5.2.2.2.   FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.3.5.2.2.3.   FRANCE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.3.5.2.3.    FRANCE IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.3.5.2.4.    FRANCE IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.3.5.3.    UK

8.3.5.3.1.    UK IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.3.5.3.2.    UK IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.3.5.3.2.1.   UK IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.3.5.3.2.2.   UK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.3.5.3.2.3.   UK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.3.5.3.3.    UK IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.3.5.3.4.    UK IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.3.5.4.    ITALY

8.3.5.4.1.    ITALY IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.3.5.4.2.    ITALY IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.3.5.4.2.1.   ITALY IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.3.5.4.2.2.   ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.3.5.4.2.3.   ITALY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.3.5.4.3.    ITALY IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.3.5.4.4.    ITALY IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.3.5.5.    SPAIN

8.3.5.5.1.    SPAIN IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.3.5.5.2.    SPAIN IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.3.5.5.2.1.   SPAIN IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.3.5.5.2.2.   SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.3.5.5.2.3.   SPAIN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.3.5.5.3.    SPAIN IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.3.5.5.4.    SPAIN IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.3.5.6.    REST OF EUROPE

8.3.5.6.1.    REST OF EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.3.5.6.2.    REST OF EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.3.5.6.2.1.   REST OF EUROPE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.3.5.6.2.2.   REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.3.5.6.2.3.   REST OF EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.3.5.6.3.    REST OF EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.3.5.6.4.    REST OF EUROPE IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.4.     ASIA-PACIFIC

8.4.1        ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.4.2        ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.4.2.1.    ASIA-PACIFIC IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.4.2.2.    ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.4.2.3.    ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.4.3        ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.4.4        ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.4.5        ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY

8.4.5.1.    INDIA

8.4.5.1.1.    INDIA IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.4.5.1.2.    INDIA IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.4.5.1.2.1.   INDIA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.4.5.1.2.2.   INDIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.4.5.1.2.3.   INDIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.4.5.1.3.    INDIA IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.4.5.1.4.    INDIA IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.4.5.2.    CHINA

8.4.5.2.1.    CHINA IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.4.5.2.2.    CHINA IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.4.5.2.2.1.   CHINA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.4.5.2.2.2.   CHINA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.4.5.2.2.3.   CHINA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.4.5.2.3.    CHINA IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.4.5.2.4.    CHINA IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.4.5.3.    JAPAN

8.4.5.3.1.    JAPAN IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.4.5.3.2.    JAPAN IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.4.5.3.2.1.   JAPAN IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.4.5.3.2.2.   JAPAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.4.5.3.2.3.   JAPAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.4.5.3.3.    JAPAN IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.4.5.3.4.    JAPAN IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.4.5.4.    AUSTRALIA

8.4.5.4.1.    AUSTRALIA IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.4.5.4.2.    AUSTRALIA IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.4.5.4.2.1.   AUSTRALIA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.4.5.4.2.2.   AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.4.5.4.2.3.   AUSTRALIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.4.5.4.3.    AUSTRALIA IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.4.5.4.4.    AUSTRALIA IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.4.5.5.    SOUTH KOREA

8.4.5.5.1.    SOUTH KOREA IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.4.5.5.2.    SOUTH KOREA IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.4.5.5.2.1.   SOUTH KOREA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.4.5.5.2.2.   SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.4.5.5.2.3.   SOUTH KOREA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.4.5.5.3.    SOUTH KOREA IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.4.5.5.4.    SOUTH KOREA IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.4.5.6.    REST OF ASIA-PACIFIC

8.4.5.6.1.    REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.4.5.6.2.    REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.4.5.6.2.1.   REST OF ASIA-PACIFIC IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.4.5.6.2.2.   REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.4.5.6.2.3.   REST OF ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.4.5.6.3.    REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.4.5.6.4.    REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.5.     REST OF WORLD

8.5.1        REST OF WORLD IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.5.2        REST OF WORLD IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.5.2.1.    REST OF WORLD IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.5.2.2.    REST OF WORLD MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.5.2.3.    REST OF WORLD CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.5.3        REST OF WORLD IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.5.4        REST OF WORLD IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.5.5        REST OF WORLD IN VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY

8.5.5.1.    LATIN AMERICA

8.5.5.1.1.    LATIN AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.5.5.1.2.    LATIN AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.5.5.1.2.1.   LATIN AMERICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.5.5.1.2.2.   LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.5.5.1.2.3.   LATIN AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.5.5.1.3.    LATIN AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.5.5.1.4.    LATIN AMERICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.5.5.2.    MIDDLE EAST

8.5.5.2.1.    MIDDLE EAST IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.5.5.2.2.    MIDDLE EAST IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.5.5.2.2.1.   MIDDLE EAST IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.5.5.2.2.2.   MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.5.5.2.2.3.   MIDDLE EAST CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.5.5.2.3.    MIDDLE EAST IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.5.5.2.4.    MIDDLE EAST IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

8.5.5.3.    AFRICA

8.5.5.3.1.    AFRICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT TYPE

8.5.5.3.2.    AFRICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNIQUE

8.5.5.3.2.1.   AFRICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE

8.5.5.3.2.2.   AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

8.5.5.3.2.3.   AFRICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

8.5.5.3.3.    AFRICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION

8.5.5.3.4.    AFRICA IN VITRO DIAGNOSTICS (IVD) MARKET, BY ENDUSER

9.    COMPANY PROFILES

9.1.     BIOMERIEUX

9.1.1        COMPANY OVERVIEW

9.1.2        COMPANY SNAPSHOT

9.1.3        OPERATING BUSINESS SEGMENTS

9.1.5        BUSINESS PERFORMANCE

9.1.6        SALES BY BUSINESS SEGMENT

9.1.7        SALES BY GEOGRAPHIC SEGMENT

9.1.8        KEY STRATEGIC MOVES & DEVELOPMENTS

9.1.9        PRIMARY MARKET COMPETITORS

9.2.     ROCHE HOLDING

9.2.1        COMPANY OVERVIEW

9.2.2        COMPANY SNAPSHOT

9.2.3        OPERATING BUSINESS SEGMENTS

9.2.5        BUSINESS PERFORMANCE

9.2.6        SALES BY BUSINESS SEGMENT

9.2.7        SALES BY GEOGRAPHIC SEGMENT

9.2.8        KEY STRATEGIC MOVES & DEVELOPMENTS

9.2.9        PRIMARY MARKET COMPETITORS

9.3.     BIO-RAD LABORATORIES, INC.

9.3.1        COMPANY OVERVIEW

9.3.2        COMPANY SNAPSHOT

9.3.3        OPERATING BUSINESS SEGMENTS

9.3.4        PRODUCT PORTFOLIO

9.3.5        BUSINESS PERFORMANCE

9.3.6        SALES BY GEOGRAPHIC SEGMENT

9.3.7        BIO-RAD LABORATORIES, INC: BUSINESS SEGMENT

9.3.8        SALES BY GEOGRAPHIC SEGMENT

9.3.9        BIO-RAD LABORATORIES, INC: GEOGRAPHIC SEGMENT

9.3.10     KEY STRATEGIC MOVES & DEVELOPMENTS

9.3.11     PRIMARY MARKET COMPETITORS

9.4.     BECTON, DICKINSON AND COMPANY

9.4.1        COMPANY OVERVIEW

9.4.2        COMPANY SNAPSHOT

9.4.3        OPERATING BUSINESS SEGMENTS

9.4.4        PRODUCT PORTFOLIO

9.4.5        BUSINESS PERFORMANCE

9.4.6        SALES BY BUSINESS SEGMENT

9.4.7        BECTON, DICKINSON AND COMPANY: BUSINESS SEGMENT

9.4.8        SALES BY GEOGRAPHIC SEGMENT

9.4.9        BECTON, DICKINSON AND COMPANY: GEOGRAPHIC SEGMENT

9.4.10     KEY STRATEGIC MOVES & DEVELOPMENTS

9.4.11     PRIMARY MARKET COMPETITORS

9.5.     SIEMENS HEALTHINEERS AG

9.5.1        COMPANY OVERVIEW

9.5.2        COMPANY SNAPSHOT

9.5.3        OPERATING BUSINESS SEGMENTS

9.5.4        PRODUCT PORTFOLIO

9.5.5        BUSINESS PERFORMANCE

9.5.6        SALES BY BUSINESS SEGMENT

9.5.7        SALES BY GEOGRAPHIC SEGMENT

9.5.8        KEY STRATEGIC MOVES & DEVELOPMENTS

9.5.9        PRIMARY MARKET COMPETITORS

9.6.     SYSMEX CORPORATION

9.6.1        COMPANY OVERVIEW

9.6.2        COMPANY SNAPSHOT

9.6.3        OPERATING BUSINESS SEGMENTS

9.6.4        PRODUCT PORTFOLIO

9.6.5        BUSINESS PERFORMANCE

9.6.6        SALES BY BUSINESS SEGMENT

9.6.7        SALES BY GEOGRAPHIC SEGMENT

9.6.8        KEY STRATEGIC MOVES & DEVELOPMENTS

9.6.9        PRIMARY MARKET COMPETITORS

9.7.     THERMO FISHER SCIENTIFIC INC.

9.7.1        COMPANY OVERVIEW

9.7.2        COMPANY SNAPSHOT

9.7.3        OPERATING BUSINESS SEGMENTS

9.7.4        PRODUCT PORTFOLIO

9.7.5        BUSINESS PERFORMANCE

9.7.6        SALES BY BUSINESS SEGMENT

9.7.7        SALES BY GEOGRAPHIC SEGMENT

9.7.8        KEY STRATEGIC MOVES & DEVELOPMENTS

9.7.9        PRIMARY MARKET COMPETITORS

9.8.     ABBOTT LABORATORIES

9.8.1        COMPANY OVERVIEW

9.8.2        COMPANY SNAPSHOT

9.8.3        OPERATING BUSINESS SEGMENTS

9.8.4        PRODUCT PORTFOLIO

9.8.5        BUSINESS PERFORMANCE

9.8.6        SALES BY BUSINESS SEGMENT

9.8.7        SALES BY GEOGRAPHIC SEGMENT

9.8.8        KEY STRATEGIC MOVES & DEVELOPMENTS

9.8.9        PRIMARY MARKET COMPETITORS

9.9.     QIAGEN N.V.

9.9.1        COMPANY OVERVIEW

9.9.2        COMPANY SNAPSHOT

9.9.3        PRODUCT PORTFOLIO

9.9.4        BUSINESS PERFORMANCE

9.9.5        SALES BY GEOGRAPHIC SEGMENT

9.9.6        KEY STRATEGIC MOVES & DEVELOPMENTS

9.9.7        PRIMARY MARKET COMPETITORS

9.10.   DANAHER CORPORATION

9.10.1     COMPANY OVERVIEW

9.10.2     COMPANY SNAPSHOT

9.10.3     OPERATING BUSINESS SEGMENTS

9.10.4     PRODUCT PORTFOLIO

9.10.5     BUSINESS PERFORMANCE

9.10.6     SALES BY BUSINESS SEGMENT

9.10.7     KEY STRATEGIC MOVES & DEVELOPMENTS

9.10.8     PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 2. REAGENTS  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 3. INSTRUMENTS  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 4. SOFTWARE AND SERVICES MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 5. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 6. GLOBAL IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 7. ELISA MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 8. RAPID TESTS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 9. ELISPOT  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 10. RADIOIMMUNOASSAY (RIA) MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 11. WESTERN BLOT MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 12. IMMUNODIAGNOSTICS  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 13. HEMATOLOGY MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 15. PCR MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 16. INAAT  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 17. HYBRIDIZATION  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 18. DNA DIAGNOSTICS  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 19. MICROARRAY  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 20. OTHERS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 21. MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 22. TISSUE DISGNOSTICS  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 23. GLOBAL CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 24. BASIC METABOLIC PANEL  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 25. LIVER PANEL MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 26. RENAL PROFILE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 27. LIPID PROFILE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 28. THYROID FUNCTION PANEL  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 29. ELECTROLYTE PANEL  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 30. SPECIALITY CHEMICALS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 31. CLINICAL CHEMISTRY  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 32. OTHER IVD TECHNIQUES MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 33. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 34. INFECTIOUS DISEASES  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 35. CANCER  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 36. CARDIAC DISEASES  MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 37. IMMUNE SYSTEM DISORDERS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 38. NEPHROLOGICAL DISEASES MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 39. GASTROINTESTINAL DISEASES MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 40. OTHER INDICATIONS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 41. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 42. STAND ALONE LABORATORY MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 43. HOSPITALS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 44. ACADEMICS AND MEDICAL SCHOOLS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 45. POINT OF CARE TESTING MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 46. OTHERS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 47. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 48. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 49. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 50. NORTH AMERICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 51. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 52. NORTH AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 53. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 54. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 55. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY COUNTRY, 2021-2030, MILLION USD

TABLE 56. U.S. IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 57. U.S. IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 58. U.S. IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 59. U.S. MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 60. U.S. CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 61. U.S. IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 62. U.S. IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 63. CANADA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 64. CANADA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 65. CANADA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 66. CANADA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 67. CANADA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 68. CANADA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 69. CANADA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 70. MEXICO IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 71. MEXICO IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 72. MEXICO IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 73. MEXICO MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 74. MEXICO CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 75. MEXICO IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 76. MEXICO IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 77. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 78. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 79. EUROPE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 80. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 81. EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 82. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 83. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 84. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY COUNTRY, 2021-2030, MILLION USD

TABLE 85. GERMANY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 86. GERMANY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 87. GERMANY IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 88. GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 89. GERMANY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 90. GERMANY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 91. GERMANY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 92. FRANCE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 93. FRANCE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 94. FRANCE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 95. FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 96. FRANCE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 97. FRANCE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 98. FRANCE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 99. UK IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 100. UK IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 101. UK IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 102. UK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 103. UK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 104. UK IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 105. UK IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 106. ITALY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 107. ITALY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 108. ITALY IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 109. ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 110. ITALY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 111. ITALY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 112. ITALY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 113. SPAIN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 114. SPAIN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 115. SPAIN IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 116. SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 117. SPAIN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 118. SPAIN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 119. SPAIN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 120. REST OF EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 121. REST OF EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 122. REST OF EUROPE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 123. REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 124. REST OF EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 125. REST OF EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 126. REST OF EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 127. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 128. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 129. ASIA-PACIFIC IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 130. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 131. ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 132. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 133. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 134. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY COUNTRY, 2021-2030, MILLION USD

TABLE 135. INDIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 136. INDIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 137. INDIA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 138. INDIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 139. INDIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 140. INDIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 141. INDIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 142. CHINA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 143. CHINA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 144. CHINA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 145. CHINA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 146. CHINA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 147. CHINA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 148. CHINA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 149. JAPAN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 150. JAPAN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 151. JAPAN IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 152. JAPAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 153. JAPAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 154. JAPAN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 155. JAPAN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 156. AUSTRALIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 157. AUSTRALIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 158. AUSTRALIA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 159. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 160. AUSTRALIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 161. AUSTRALIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 162. AUSTRALIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 163. SOUTH KOREA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 164. SOUTH KOREA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 165. SOUTH KOREA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 166. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 167. SOUTH KOREA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 168. SOUTH KOREA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 169. SOUTH KOREA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 170. REST OF ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 171. REST OF ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 172. REST OF ASIA-PACIFIC IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 173. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 174. REST OF ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 175. REST OF ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 176. REST OF ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 177. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 178. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 179. REST OF WORLD IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 180. REST OF WORLD MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 181. REST OF WORLD CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 182. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 183. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 184. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY COUNTRY, 2021-2030, MILLION USD

TABLE 185. LATIN AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 186. LATIN AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 187. LATIN AMERICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 188. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 189. LATIN AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 190. LATIN AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 191. LATIN AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 192. MIDDLE EAST IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 193. MIDDLE EAST IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 194. MIDDLE EAST IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 195. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 196. MIDDLE EAST CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 197. MIDDLE EAST IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 198. MIDDLE EAST IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 199. AFRICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

TABLE 200. AFRICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 201. AFRICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 202. AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 203. AFRICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

TABLE 204. AFRICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

TABLE 205. AFRICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

TABLE 206. BIOMERIEUX: COMPANY SNAPSHOT

TABLE 207. BIOMERIEUX: OPERATING SEGMENTS

TABLE 208. BIOMERIEUX: PRODUCT PORTFOLIO

TABLE 209. BIOMERIEUX: BUSINESS SEGMENT

TABLE 210. BIOMERIEUX: GEOGRAPHIC SEGMENT

TABLE 211. BIOMERIEUX: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 212. ROCHE HOLDING: COMPANY SNAPSHOT

TABLE 213. BIOMERIEUX: OPERATING SEGMENTS

TABLE 214. ROCHE HOLDINGS: PRODUCT PORTFOLIO

TABLE 215. ROCHE HOLDINGS: BUSINESS SEGMENT

TABLE 216. ROCHE HOLDINGS: GEOGRAPHIC SEGMENT

TABLE 217. ROCHE HOLDING: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 218. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT

TABLE 219. BIO-RAD LABORATORIES, INC: OPERATING SEGMENTS

TABLE 220. BIO-RAD LABORATORIES, INC: PRODUCT PORTFOLIO

TABLE 221. BIO-RAD LABORATORIES: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 222. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT

TABLE 223. BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS

TABLE 224. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO

TABLE 225. BECTON, DICKINSON AND COMPANY: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 226. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT

TABLE 227. SIEMENS HEALTHINEERS AG: OPERATING SEGMENTS

TABLE 228. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO

TABLE 229. SIEMENS HEALTHINEERS AG: BUSINESS SEGMENT

TABLE 230. SIEMENS HEALTHINEERS AG: GEOGRAPHIC SEGMENT

TABLE 231. SIEMENS HEALTHINEERS AG: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 232. SYSMEX CORPORATION: COMPANY SNAPSHOT

TABLE 233. SYSMEX CORPORATION: OPERATING SEGMENTS

TABLE 234. SYSMEX CORPORATION: PRODUCT PORTFOLIO

TABLE 235. SYSMEX CORPORATION: BUSINESS SEGMENT

TABLE 236. SYSMEX CORPORATION: GEOGRAPHIC SEGMENT

TABLE 237. SYSMEX CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 238. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 239. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 240. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 241. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT

TABLE 242. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT

TABLE 243. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 244. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 245. ABBOTT LABORATORIES: BUSINESS SEGMENTS

TABLE 246. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 247. ABBOTT LABORATORIES: BUSINESS SEGMENT

TABLE 248. ABBOTT LABORATORIES: GEOGRAPHIC SEGMENT

TABLE 249. ABBOTT LABORATORIES: KEY STRATEGIC MOVES & DEVELOPMENT

TABLE 250. QIAGEN N.V.: COMPANY SNAPSHOT

TABLE 251. QIAGEN N.V.: PRODUCT PORTFOLIO

TABLE 252. QIAGEN N.V.: GEOGRAPHIC SEGMENT

TABLE 253. QIAGEN N.V.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 254. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 255. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 256. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 257. DANAHER CORPORATION: BUSINESS SEGMENT

TABLE 258. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 2. REAGENTS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 3. INSTRUMENTS  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 4. SOFTWARE AND SERVICES MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 5. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 6. GLOBAL IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 7. ELISA MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 8. RAPID TESTS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 9. ELISPOT  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 10. RADIOIMMUNOASSAY (RIA) MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 11. WESTERN BLOT MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 12. IMMUNODIAGNOSTICS  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 13. HEMATOLOGY MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 15. PCR MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 16. INAAT  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 17. HYBRIDIZATION MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 18. DNA DIAGNOSTICS  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 19. MICROARRAY  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 20. OTHERS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 21. MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 22. TISSUE DISGNOSTICS  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 23. GLOBAL CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 24. BASIC METABOLIC PANEL  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 25. LIVER PANEL MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 26. RENAL PROFILE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 27. LIPID PROFILE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 28. THYROID FUNCTION PANEL  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 29. ELECTROLYTE PANEL  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 30. SPECIALITY CHEMICALS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 31. CLINICAL CHEMISTRY  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 32. OTHER IVD TECHNIQUES MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 33. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 34. INFECTIOUS DISEASES  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 35. CANCER  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 36. CARDIAC DISEASES  MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 37. IMMUNE SYSTEM DISORDERS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 38. NEPHROLOGICAL DISEASES MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 39. GASTROINTESTINAL DISEASES MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 40. OTHER INDICATIONS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 41. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 42. STAND ALONE LABORATORY MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 43. HOSPITALS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 44. ACADEMICS AND MEDICAL SCHOOLS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 45. POINT OF CARE TESTING MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 46. OTHERS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 47. GLOBAL IN VIRTO DIAGNOSTIC (IVD) MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 48. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 49. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 50. NORTH AMERICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 51. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 52. NORTH AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 53. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 54. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 55. NORTH AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 56. U.S. IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 57. U.S. IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 58. U.S. IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 59. U.S. MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 60. U.S. CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 61. U.S. IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 62. U.S. IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 63. CANADA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 64. CANADA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 65. CANADA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 66. CANADA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 67. CANADA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 68. CANADA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 69. CANADA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 70. MEXICO IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 71. MEXICO IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 72. MEXICO IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 73. MEXICO MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 74. MEXICO CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 75. MEXICO IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 76. MEXICO IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 77. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 78. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 79. EUROPE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 80. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 81. EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 82. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 83. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 84. EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 85. GERMANY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 86. GERMANY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 87. GERMANY IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 88. GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 89. GERMANY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 90. GERMANY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 91. GERMANY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 92. FRANCE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 93. FRANCE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 94. FRANCE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 95. FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 96. FRANCE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 97. FRANCE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 98. FRANCE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 99. UK IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 100. UK IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 101. UK IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 102. UK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 103. UK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 104. UK IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 105. UK IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 106. ITALY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 107. ITALY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 108. ITALY IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 109. ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 110. ITALY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 111. ITALY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 112. ITALY IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 113. SPAIN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 114. SPAIN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 115. SPAIN IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 116. SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 117. SPAIN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 118. SPAIN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 119. SPAIN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 120. REST OF EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 121. REST OF EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 122. REST OF EUROPE IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 123. REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 124. REST OF EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 125. REST OF EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 126. REST OF EUROPE IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 127. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 128. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 129. ASIA-PACIFIC IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 130. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 131. ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 132. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 133. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 134. ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 135. INDIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 136. INDIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 137. INDIA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 138. INDIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 139. INDIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 140. INDIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 141. INDIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 142. CHINA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 143. CHINA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 144. CHINA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 145. CHINA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 146. CHINA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 147. CHINA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 148. CHINA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 149. JAPAN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 150. JAPAN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 151. JAPAN IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 152. JAPAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 153. JAPAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 154. JAPAN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 155. JAPAN IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 156. AUSTRALIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 157. AUSTRALIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 158. AUSTRALIA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 159. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 160. AUSTRALIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 161. AUSTRALIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 162. AUSTRALIA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 163. SOUTH KOREA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 164. SOUTH KOREA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 165. SOUTH KOREA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 166. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 167. SOUTH KOREA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 168. SOUTH KOREA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 169. SOUTH KOREA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 170. REST OF ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 171. REST OF ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 172. REST OF ASIA-PACIFIC IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 173. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 174. REST OF ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 175. REST OF ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 176. REST OF ASIA-PACIFIC IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 177. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 178. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 179. REST OF WORLD IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 180. REST OF WORLD MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 181. REST OF WORLD CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 182. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 183. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 184. REST OF WORLD IN VIRTO DIAGNOSTIC (IVD) MARKET, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 185. LATIN AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 186. LATIN AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 187. LATIN AMERICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 188. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 189. LATIN AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 190. LATIN AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 191. LATIN AMERICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 192. MIDDLE EAST IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 193. MIDDLE EAST IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 194. MIDDLE EAST IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 195. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 196. MIDDLE EAST CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 197. MIDDLE EAST IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 198. MIDDLE EAST IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 199. AFRICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY PRODUCT TYPE, 2021-2030, MILLION USD

FIGURE 200. AFRICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 201. AFRICA IMMUNODIAGNOSTICS  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 202. AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 203. AFRICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2021-2030, MILLION USD

FIGURE 204. AFRICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY APPLICATION, 2021-2030, MILLION USD

FIGURE 205. AFRICA IN VIRTO DIAGNOSTIC (IVD) MARKET, BY ENDUSER, 2021-2030, MILLION USD

FIGURE 206. BIOMERIEUX: NET SALES, 2019–2021 ($MILLION)

FIGURE 207. BIOMERIEUX.: PRIMARY MARKET COMPETITORS

FIGURE 208. ROCHE HOLDING: NET SALES, 2019–2021 ($MILLION)

FIGURE 209. ROCHE HOLDING: PRIMARY MARKET COMPETITORS

FIGURE 210. BIO-RAD LABORATORIES, INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 211. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 212. BECTON, DICKINSON AND COMPANY: NET SALES, 2020- 2022 ($MILLION)

FIGURE 213. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 214. SIEMENS HEALTHINEERS AG: NET SALES, 2019–2021 ($MILLION)

FIGURE 215. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS

FIGURE 216. SYSMEX CORPORATION: NET SALES, 2019–2021 ($MILLION)

FIGURE 217. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 218. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)

FIGURE 219. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS

FIGURE 220. ABBOTT LABORATORIES: NET SALES, 2019–2021 (USD MILLION)

FIGURE 221. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS

FIGURE 222. QIAGEN N.V.: NET SALES, 2019–2021 ($MILLION)

FIGURE 223. QIAGEN N.V.: PRIMARY MARKET COMPETITORS

FIGURE 224. DANAHER CORPORATION: NET SALES, 2019–2021 ($MILLION)

FIGURE 225. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Biomerieux

  • Sysmex Corporation

  • Qiagen N.V.

  • Bio-Rad Laboratories, Inc.

  • Becton, Dickinson and Company

  • Roche Holding

  • Abbott Laboratories

  • Danaher Corporation

  • Siemens Healthineers AG

  • Thermo Fisher Scientific Inc.


Frequently Asked Questions
1. Which are the top five companies in the in vitro diagnostic industry?

BioMerieux, Sysmex Corporation, Qiagen N.V., Bio Rad Laboratories Incorporation., and Beckton, Dickinson & Company.

Why is the U.S. in vitro diagnostic industry highly lucrative?

The U.S. market is mainly driven by an aging population, increasing incidences of chronic diseases, and advances in diagnostic technologies.

Which sector has the highest share in adoption of IVD equipment?

The standalone laboratory sector is highest in adoption of in vitro diagnostics.

Which is the fastest growing region for the IVD market?

Asia-Pacific is the fastest-growing region, and is anticipated to grow at a CAGR of 3.46% to reach USD 28.65 billion by 2030 from USD 19.89 billion in 2021.

What would be the worth of the global in vitro diagnostic market by 2030?

According to the report published by Next Move Strategy Consulting, the in vitro diagnostic industry is expected to reach USD 118.57 billion by 2030